Mineralys to present lorundrostat data at AHA hypertension sessions 2026
Mineralys Therapeutics announced that five abstracts will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026 in Arlington, Virginia, October 7–11. The presentations involve lorundrostat, a selective aldosterone synthase inhibitor, in studies related to hypertension and obstructive sleep apnea (OSA).
What is lorundrostat and why it matters
Lorundrostat is a drug designed to limit production of aldosterone, a hormone that can raise blood pressure and contribute to heart and kidney problems when levels are too high. Mineralys is highlighting several studies, including a randomized crossover trial called Explore-OSA, which looks at lorundrostat in people with moderate-to-severe OSA and hypertension. The key idea is that reducing aldosterone production could help lower blood pressure and lessen related risks in people with these conditions.
Key facts about the presentations
Five abstracts will be shown at the AHA Hypertension Scientific Sessions 2026. The oral presentation is titled: “Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Obstructive Sleep Apnea and Hypertension: Explore-OSA Randomized Crossover Trial,” led by Reena Mehra from the University of Washington. A separate poster discusses blood pressure responder analysis in the Global Launch-HTN trial of lorundrostat. Presentations are part of a broader set of investigations into how lowering aldosterone affects hypertension and conditions like sleep apnea.
Who might be affected by the findings
The research targets adults with high blood pressure linked to obstructive sleep apnea, a condition where breathing repeatedly stops and starts during sleep. If lorundrostat shows favorable results, it could influence future treatment options for this subgroup and potentially reduce cardiovascular risks associated with aldosterone-related mechanisms. Until results are published, no changes to standard care should be assumed.
Practical next steps for readers
If you’re monitoring hypertension or sleep apnea, talk with your healthcare provider about current treatment plans and how new research could influence future options. Look for official study results and peer-reviewed publications from the AHA sessions to understand efficacy, safety, and how widely applicable the findings are. For now, treatment decisions should continue to be based on established guidelines and physician advice.
Limits of the information and questions to watch
The source only notes upcoming presentations and abstracts; it does not provide full data or results. Important questions include the magnitude of blood pressure change, long-term safety, and how lorundrostat performs across diverse patient groups. Readers should await the complete study reports and independent reviews to gauge clinical impact.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- biospace.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.